Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin.
<h4>Background</h4>Previous studies have extensively documented antimicrobial and chemotactic activities of beta-defensins. Human beta-defensin-2 (hBD-2) is strongly expressed in lesional psoriatic epidermis, and recently we have shown that high beta-defensin genomic copy number is assoc...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b6b1e9ff82104ec2b1aca2b327370234 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b6b1e9ff82104ec2b1aca2b327370234 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b6b1e9ff82104ec2b1aca2b3273702342021-11-25T06:16:53ZBeta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin.1932-620310.1371/journal.pone.0004725https://doaj.org/article/b6b1e9ff82104ec2b1aca2b3273702342009-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19266104/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Previous studies have extensively documented antimicrobial and chemotactic activities of beta-defensins. Human beta-defensin-2 (hBD-2) is strongly expressed in lesional psoriatic epidermis, and recently we have shown that high beta-defensin genomic copy number is associated with psoriasis susceptibility. It is not known, however, if biologically and pathophysiologically relevant concentrations of hBD-2 protein are present in vivo, which could support an antimicrobial and proinflammatory role of beta-defensins in lesional psoriatic epidermis.<h4>Methodology/principal findings</h4>We found that systemic levels of hBD-2 showed a weak but significant correlation with beta defensin copy number in healthy controls but not in psoriasis patients with active disease. In psoriasis patients but not in atopic dermatitis patients, we found high systemic hBD-2 levels that strongly correlated with disease activity as assessed by the PASI score. Our findings suggest that systemic levels in psoriasis are largely determined by secretion from involved skin and not by genomic copy number. Modelling of the in vivo epidermal hBD-2 concentration based on the secretion rate in a reconstructed skin model for psoriatic epidermis provides evidence that epidermal hBD-2 levels in vivo are probably well above the concentrations required for in vitro antimicrobial and chemokine-like effects.<h4>Conclusions/significance</h4>Serum hBD-2 appears to be a useful surrogate marker for disease activity in psoriasis. The discrepancy between hBD-2 levels in psoriasis and atopic dermatitis could explain the well known differences in infection rate between these two diseases.Patrick A M JansenDiana Rodijk-OlthuisEdward J HolloxMarijke KamsteegGeuranne S TjabringaGys J de JonghIvonne M J J van Vlijmen-WillemsJudith G M BergboerMichelle M van RossumElke M G J de JongMartin den HeijerAndrea W M EversMieke BergersJohn A L ArmourPatrick L J M ZeeuwenJoost SchalkwijkPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 4, Iss 3, p e4725 (2009) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Patrick A M Jansen Diana Rodijk-Olthuis Edward J Hollox Marijke Kamsteeg Geuranne S Tjabringa Gys J de Jongh Ivonne M J J van Vlijmen-Willems Judith G M Bergboer Michelle M van Rossum Elke M G J de Jong Martin den Heijer Andrea W M Evers Mieke Bergers John A L Armour Patrick L J M Zeeuwen Joost Schalkwijk Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. |
| description |
<h4>Background</h4>Previous studies have extensively documented antimicrobial and chemotactic activities of beta-defensins. Human beta-defensin-2 (hBD-2) is strongly expressed in lesional psoriatic epidermis, and recently we have shown that high beta-defensin genomic copy number is associated with psoriasis susceptibility. It is not known, however, if biologically and pathophysiologically relevant concentrations of hBD-2 protein are present in vivo, which could support an antimicrobial and proinflammatory role of beta-defensins in lesional psoriatic epidermis.<h4>Methodology/principal findings</h4>We found that systemic levels of hBD-2 showed a weak but significant correlation with beta defensin copy number in healthy controls but not in psoriasis patients with active disease. In psoriasis patients but not in atopic dermatitis patients, we found high systemic hBD-2 levels that strongly correlated with disease activity as assessed by the PASI score. Our findings suggest that systemic levels in psoriasis are largely determined by secretion from involved skin and not by genomic copy number. Modelling of the in vivo epidermal hBD-2 concentration based on the secretion rate in a reconstructed skin model for psoriatic epidermis provides evidence that epidermal hBD-2 levels in vivo are probably well above the concentrations required for in vitro antimicrobial and chemokine-like effects.<h4>Conclusions/significance</h4>Serum hBD-2 appears to be a useful surrogate marker for disease activity in psoriasis. The discrepancy between hBD-2 levels in psoriasis and atopic dermatitis could explain the well known differences in infection rate between these two diseases. |
| format |
article |
| author |
Patrick A M Jansen Diana Rodijk-Olthuis Edward J Hollox Marijke Kamsteeg Geuranne S Tjabringa Gys J de Jongh Ivonne M J J van Vlijmen-Willems Judith G M Bergboer Michelle M van Rossum Elke M G J de Jong Martin den Heijer Andrea W M Evers Mieke Bergers John A L Armour Patrick L J M Zeeuwen Joost Schalkwijk |
| author_facet |
Patrick A M Jansen Diana Rodijk-Olthuis Edward J Hollox Marijke Kamsteeg Geuranne S Tjabringa Gys J de Jongh Ivonne M J J van Vlijmen-Willems Judith G M Bergboer Michelle M van Rossum Elke M G J de Jong Martin den Heijer Andrea W M Evers Mieke Bergers John A L Armour Patrick L J M Zeeuwen Joost Schalkwijk |
| author_sort |
Patrick A M Jansen |
| title |
Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. |
| title_short |
Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. |
| title_full |
Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. |
| title_fullStr |
Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. |
| title_full_unstemmed |
Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. |
| title_sort |
beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2009 |
| url |
https://doaj.org/article/b6b1e9ff82104ec2b1aca2b327370234 |
| work_keys_str_mv |
AT patrickamjansen betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT dianarodijkolthuis betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT edwardjhollox betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT marijkekamsteeg betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT geurannestjabringa betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT gysjdejongh betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT ivonnemjjvanvlijmenwillems betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT judithgmbergboer betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT michellemvanrossum betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT elkemgjdejong betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT martindenheijer betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT andreawmevers betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT miekebergers betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT johnalarmour betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT patrickljmzeeuwen betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin AT joostschalkwijk betadefensin2proteinisaserumbiomarkerfordiseaseactivityinpsoriasisandreachesbiologicallyrelevantconcentrationsinlesionalskin |
| _version_ |
1718414004687208448 |